{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:48:04Z","timestamp":1779313684914,"version":"3.51.4"},"reference-count":17,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"published-print":{"date-parts":[[2020,2,17]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Derangements in monoaminergic transmission in the substantia nigra with disturbed signaling in the hypothalamic-pituitary-adrenal axis are the major characteristics of Parkinson\u2019s disease (PD). It has been reported that the administration of hydrogen sulfide (H2S) is in practice to treat PD because of its redundant nature in regulating various neuronal signals. Hence, the current investigation was performed to evaluate the hypothesis that H2S might exert protective action via the inhibition of epigenetic histone acetylation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>To test this notion, 6-hydroxydopamine (6-OHDA) was used to induce PD and sodium hydrogen sulfide (SHS) was used as a\u00a0H2S donor and tubastatin A\u00a0(TSA) was tested in an in vivo rat model to delineate the signaling mechanism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Induction of PD in rats demonstrated elevated oxidative stress with an evidenced decrease in antioxidant enzymes, while elevated pro-inflammatory cytokines and inflammatory mediators were observed in the striatum of PD rats compared to controls. On the other hand, elevated (p &lt; 0.01) levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), mRNA transcript of HDAC-2, -3, -4, -6 and total histone deacetylase (HDAC) were found with reduced levels of histone acetyltransferase (HAT) in the brain tissues of PD induced rats.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Diversely, H2S exposure reversed these alterations with reduced HDAC activity. Further, PD rats treated with HDAC inhibitor showed a\u00a0dramatic upsurge in the level of tyrosine hydroxylase, with a\u00a0decreased level of glial fibrillary acidic protein, \uf061-synuclein, tumor necrosis factor \uf061, and other cytokines. Thus the results of the study suggest that H2S exerts protection via inhibition of HDAC.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms.2020.93121","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T14:10:20Z","timestamp":1590156620000},"source":"Crossref","is-referenced-by-count":8,"title":["Protective effect of hydrogen sulfide is mediated \nby negative regulation of epigenetic histone acetylation in Parkinson\u2019s disease"],"prefix":"10.5114","author":[{"given":"Yang","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, The Second Affiliated Hospital of Xi\u2019an\nMedical University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Chang Hai Hospital, Naval Military Medical University,\nShanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqiang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Second Affiliated Hospital of Xi\u2019an Medica University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haikang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Affiliated Hospital of Xi\u2019an Medical University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, The Second Affiliated Hospital of Xi\u2019an\nMedical University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, The Second Affiliated Hospital of Xi\u2019an\nMedical University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Second Affiliated Hospital of Xi\u2019an Medical University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"ref-459433","first-page":"176","article-title":"Leczenierakapiersi u m\u0119\u017cczyzn\u2013opisprzypadku. Treatment of male breast cancer\u2013case report","volume":"9","author":"Pietrzy\u0144ski \u0141","year":"2017","unstructured":"Pietrzy\u0144ski \u0141, Rajcher M, Pietrzy\u0144ska T. Leczenierakapiersi u m\u0119\u017cczyzn\u2013opisprzypadku. Treatment of male breast cancer\u2013case report. Med Paliat2017; 9: 176-180.","journal-title":"Med Paliat"},{"key":"ref-459434","doi-asserted-by":"crossref","first-page":"50","DOI":"10.14216\/kjco.17007","article-title":"A case report of 29-year-old male patient with breast carcinoma","volume":"13","author":"Park SY","year":"2017","unstructured":"Park SY, Cho YU, Kim SJ, Hur MH. A case report of 29-year-old male patient with breast carcinoma. Korean J Clin Oncol2017; 13: 50-53.","journal-title":"Korean J Clin Oncol"},{"key":"ref-459435","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1093\/milmed\/usz049","article-title":"Metachronous Contralateral Male Breast Cancer: Case Report and Literature Review","volume":"184","author":"O\u2019Leary TR","year":"2019","unstructured":"O\u2019Leary TR, Shriver CD, Wind G. Metachronous Contralateral Male Breast Cancer: Case Report and Literature Review. Mil Med. 2019; 184: e581-e586.","journal-title":"Mil Med"},{"key":"ref-459436","first-page":"52","article-title":"Male breast cancer\u2013case report and review of literature","volume":"2","author":"Wro\u0144ski K","year":"2014","unstructured":"Wro\u0144ski K. Male breast cancer\u2013case report and review of literature. Borgis\u2013New Medicine2014; 2: 52-54.","journal-title":"Borgis\u2013New Medicine"},{"key":"ref-459437","first-page":"478","article-title":"Male Breast Carcinoma Case Report and Review of Literature","volume":"6","author":"Mishra T","year":"2018","unstructured":"Mishra T, Kelkar R, Navare M, . Male Breast Carcinoma Case Report and Review of Literature. J Med Sci Clin Res2018; 6: 478-483.","journal-title":"J Med Sci Clin Res"},{"key":"ref-459438","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3332\/ecancer.2015.508","article-title":"Report from the 37th San Antonio breast cancer symposium, 9-13th December 2014, Texas, USA","volume":"9","author":"Ahmed M","year":"2015","unstructured":"Ahmed M, Esposito E. Report from the 37th San Antonio breast cancer symposium, 9-13th December 2014, Texas, USA. Ecancermedicalscience2015; 9: 508.","journal-title":"Ecancermedicalscience"},{"key":"ref-459439","first-page":"595","article-title":"BRCA1 and BRCA2 for men. Information for men from families with a known alteration in the BRCA1\/2 gene. Male breast cancer","volume":"367","author":"Fentiman IS","year":"2006","unstructured":"Fentiman IS, Fourquet A, Hortobagyi GN. BRCA1 and BRCA2 for men. Information for men from families with a known alteration in the BRCA1\/2 gene. Male breast cancer. Lancet2006; 367: 595-604.","journal-title":"Lancet"},{"key":"ref-459440","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: a population-based study","volume":"101","author":"Giordano SH","year":"2004","unstructured":"Giordano SH, Cohen DS, Buzdar AU, . Breast carcinoma in men: a population-based study. Cancer2004; 101: 51-57.","journal-title":"Cancer"},{"key":"ref-459441","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-0760(98)00124-1","article-title":"Proliferative activity and steroid hormone receptor status in male breast carcinoma","volume":"67","author":"Mu\u00f1oz de","year":"1998","unstructured":"Mu\u00f1oz de Toro MM, Maffini MV, Kass L, Luque EH. Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol1998; 67: 333-339.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref-459442","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/bcr2258","article-title":"Immunohistochemical characterization of subtypes of male breast carcinoma","volume":"11","author":"Ge Y","year":"2009","unstructured":"Ge Y, Sneige N, Eltorky MA, . Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res2009; 11: R28.","journal-title":"Breast Cancer Res"},{"key":"ref-459443","first-page":"45","article-title":"HER2-positive male breast cancer: an update","volume":"2","author":"Ottini L","year":"2010","unstructured":"Ottini L, Capalbo C, Rizzolo P, . HER2-positive male breast cancer: an update. Breast Cancer (Dove Med Press)2010; 2: 45-58.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref-459444","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cge.12524","article-title":"Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland","volume":"88","author":"Cybulski C","year":"2015","unstructured":"Cybulski C, Lubi\u0144ski J, Woko\u0142orczyk D, . Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clin Genet2015; 88: 366-370.","journal-title":"Clin Genet"},{"key":"ref-459445","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10689-009-9301-5","article-title":"Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing","volume":"9","author":"Diez O","year":"2010","unstructured":"Diez O, Guti\u00e9rrez-Enr\u00edquez S, Balma\u00f1a J. Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. Fam Cancer2010; 9: 187-191.","journal-title":"Fam Cancer"},{"key":"ref-459446","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/301885","article-title":"Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study","volume":"62","author":"Neuhausen SL","year":"1998","unstructured":"Neuhausen SL, Godwin AK, Gershoni-Baruch R, . Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet1998; 62: 1381-1388.","journal-title":"Am J Hum Genet"},{"key":"ref-459447","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jmg.38.2.102","article-title":"De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer","volume":"38","author":"van der","year":"2001","unstructured":"van der Luijt RB, van Zon PHA, Jansen RPM, . De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. J Med Genet2001; 38: 102-105.","journal-title":"J Med Genet"},{"key":"ref-459448","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"Rebbeck TR","year":"2018","unstructured":"Rebbeck TR, Friebel TM, Friedman E, . Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat2018; 39: 593-620.","journal-title":"Hum Mutat"},{"key":"ref-459449","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1093\/carcin\/bgt272","article-title":"The highlyprevalent BRCA2 mutation c.2808_2811del (3036delACAA) islocated in a mutational hotspot and hasmultipleorigins","volume":"34","author":"Infante M","year":"2013","unstructured":"Infante M, Dur\u00e1n M, Acedo A, . The highlyprevalent BRCA2 mutation c.2808_2811del (3036delACAA) islocated in a mutational hotspot and hasmultipleorigins. Carcinogenesis2013; 34: 2505-2511.","journal-title":"Carcinogenesis"}],"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-113025-59681","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-113025-59681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T14:21:24Z","timestamp":1635517284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Protective-effect-of-hydrogen-sulfide-is-mediated-r-nby-negative-regulation-of-epigenetic,113025,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":17,"alternative-id":["113025"],"URL":"https:\/\/doi.org\/10.5114\/aoms.2020.93121","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]}}}